Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Apollo Endosurgery, Inc.    APEN

APOLLO ENDOSURGERY, INC.

(APEN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/06/2020 07/07/2020 07/08/2020 07/09/2020 07/10/2020 Date
1.68(c) 1.63(c) 1.62(c) 1.5(c) 1.5(c) Last
39 635 30 397 13 221 22 614 14 571 Volume
+0.60% -2.98% -0.61% -7.41% 0.00% Change
More quotes
Financials (USD)
Sales 2020 36,1 M - -
Net income 2020 -32,9 M - -
Net Debt 2020 - - -
P/E ratio 2020 -1,09x
Yield 2020 -
Sales 2021 50,2 M - -
Net income 2021 -31,9 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,45x
Yield 2021 -
Capitalization 31,8 M 31,8 M -
Capi. / Sales 2020 0,88x
Capi. / Sales 2021 0,63x
Nbr of Employees 217
Free-Float 65,5%
More Financials
Company
Apollo Endosurgery, Inc., formerly Lpath, Inc., is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company's device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries. The Company's products include ORBERA, LAP-BAND and OverStitch. The Company's... 
More about the company
Surperformance© ratings of Apollo Endosurgery, Inc.
Trading Rating : - Investor Rating :
More Ratings
Latest news on APOLLO ENDOSURGERY, INC.
07/01APOLLO ENDOSURGERY, INC. : Changes in Registrant's Certifying Accountant (form 8..
AQ
05/22APOLLO ENDOSURGERY, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
05/04APOLLO ENDOSURGERY, INC. : Results of Operations and Financial Condition, Financ..
AQ
05/04APOLLO ENDOSURGERY : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION..
AQ
04/20APOLLO ENDOSURGERY, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
03/26APOLLO ENDOSURGERY : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION..
AQ
03/26APOLLO ENDOSURGERY, INC. : Results of Operations and Financial Condition, Financ..
AQ
03/05APOLLO ENDOSURGERY, INC. : Change in Directors or Principal Officers, Financial ..
AQ
2019APOLLO ENDOSURGERY, INC. : Results of Operations and Financial Condition, Financ..
AQ
2019APOLLO ENDOSURGERY : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION..
AQ
2019APOLLO ENDOSURGERY, INC. : Entry into a Material Definitive Agreement, Creation ..
AQ
2019APOLLO ENDOSURGERY, INC. : Entry into a Material Definitive Agreement, Regulatio..
AQ
2019APOLLO ENDOSURGERY : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION..
AQ
2019APOLLO ENDOSURGERY, INC. : Results of Operations and Financial Condition, Financ..
AQ
2018APOLLO ENDOSURGERY, INC. : Reports Second Quarter 2018 Results
BU
More news
News in other languages on APOLLO ENDOSURGERY, INC.
07/01APOLLO ENDOSURGERY, INC. : Changes in Registrant's Certifying Accountant (form 8..
05/22APOLLO ENDOSURGERY, INC. : Change in Directors or Principal Officers (form 8-K)
05/04APOLLO ENDOSURGERY, INC. : Results of Operations and Financial Condition, Financ..
05/04APOLLO ENDOSURGERY : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION..
04/20APOLLO ENDOSURGERY, INC. : Change in Directors or Principal Officers (form 8-K)
More news
Chart APOLLO ENDOSURGERY, INC.
Duration : Period :
Apollo Endosurgery, Inc. Technical Analysis Chart | APEN | US03767D1081 | MarketScreener
Technical analysis trends APOLLO ENDOSURGERY, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 5,00 $
Last Close Price 1,50 $
Spread / Highest target 433%
Spread / Average Target 233%
Spread / Lowest Target 33,3%
EPS Revisions
Managers
NameTitle
K. Todd Newton Chief Executive Officer & Director
John R. Barr Chairman
John Molesphini Executive Vice President-Operations
Stefanie Cavanaugh Chief Financial Officer, Secretary & Treasurer
Christopher J. Gostout Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
APOLLO ENDOSURGERY, INC.-47.37%32
ABBOTT LABORATORIES7.11%164 573
MASIMO CORPORATION46.23%12 508
ASAHI INTECC CO., LTD.-6.25%7 320
NOVOCURE LIMITED-28.35%6 065
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.95.28%5 682